Today’s PR is long on platitudes and short on consequential changes other than the previously announced restructuring of the Ofatumumab agreement with GSK (#msg-51924529).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”